The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
ELKHART, Ind.--(BUSINESS WIRE)--LCI Industries (NYSE: LCII), which, through its wholly-owned subsidiary, Lippert Components, Inc. ("Lippert"), supplies a broad array of highly engineered components fo...
With major economic weakness possibly lurking around the corner, investors should consider targeting stocks to sell. Specifically, market participants should note securities that feature rising short ...
Lannett Company, Inc. (NYSE:LCI ) Q2 2023 Earnings Conference Call February 1, 2023 4:30 PM ET Company Participants Robert Jaffe - Investor Relations Tim Crew - Chief Executive Officer John Kozlowski ...
Lannett (LCI) delivered earnings and revenue surprises of 17.07% and 10.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...
Lannett (LCI) delivered earnings and revenue surprises of 8.70% and 10.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...
Lannett Company, Inc. (NYSE:LCI ) Q1 2023 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Robert Jaffe - Investor Relations Tim Crew - Chief Executive Officer John Kozlowski ...
TREVOSE, Pa. , Oct. 26, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, a...
Lannett Company, Inc. (NYSE:LCI ) Q4 2022 Earnings Conference Call August 24, 2022 4:30 PM ET Company Participants Robert Jaffe - Investor Relations, Robert Jaffe Co., LLC Timothy Crew - Chief Executi...
TREVOSE, Pa. , Aug. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 fourth quarter and full year on Wednesday, Augu...